Retinitis Pigmentosa Market Report 2026

Retinitis Pigmentosa Market Overview

• Retinitis Pigmentosa market size has reached to $12.15 billion in 2025 • Expected to grow to $18.31 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Healthcare Expenditure Drives Growth In The Retinitis Pigmentosa Market • Market Trend: Innovative Gene Therapy Developments In Retinitis Pigmentosa • North America was the largest region in 2025.

The key promising market opportunities in the retinitis pigmentosa market include: • Autosomal Recessive (Segmentation By Type) → Expected gain of $3110.66 Million • Specialty Clinics (Segmentation By End-users) → Expected gain of $2822.82 Million • Online Pharmacy (Segmentation By Distribution Channel) → Expected gain of $2663.13 Million

What Is Covered Under Retinitis Pigmentosa Market?

Retinitis pigmentosa (RP) is a group of inherited disorders causing progressive degeneration of the retina, leading to vision loss. It primarily affects photoreceptor cells (rods and cones), resulting in symptoms such as night blindness and tunnel vision. Over time, RP can lead to significant visual impairment and blindness. The main types of retinitis pigmentosa are autosomal recessive, autosomal dominant, and x-linked. Autosomal recessive retinitis pigmentosa (AR-RP) is a form of disease where a person must inherit two copies of the mutated gene, one from each parent, to be affected. The treatment of retinitis pigmentosa includes vitamin A, docosahexaenoic acid (DHA), calcium channel blockers, gene therapy, retinal eye prosthetics, and others, and is diagnosed by electroretinogram, visual field testing, genetic testing, and others. The distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, and they are used by various end-users such as hospitals, specialty clinics, home care, and others.

What Is The Retinitis Pigmentosa Market Growth Forecast?

The retinitis pigmentosa market size is expected to see strong growth in the next few years. It will grow to $18.31 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing investments in gene therapy pipelines, rising demand for disease-modifying treatments, expansion of personalized medicine approaches, growing integration of assistive vision technologies, increasing focus on early genetic diagnosis. Major trends in the forecast period include increasing focus on gene-based therapies, rising adoption of retinal prosthetic devices, growing use of genetic testing for diagnosis, expansion of supportive vision enhancement solutions, enhanced research into disease-modifying treatments.

What Is The Driver Of The Retinitis Pigmentosa Market?

The increase in healthcare expenditure is expected to propel the growth of the retinitis pigmentosa market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare goods and services, including medical treatments, medications, hospitalizations, and preventive care, within a specified period, reflecting the overall cost of healthcare provision within a population. Healthcare expenditure is rising due to the increasing cost of advanced medical technologies, aging populations, and the prevalence of chronic diseases. Healthcare expenditure for retinitis pigmentosa is focused on advancing diagnostic methods, developing effective treatments, and providing supportive care to manage vision loss. For instance, in April 2025, according to the American Medical Association (AMA), a US-based professional association, U.S. health spending surged by 7.5% in 2023 to reach $4.9 trillion, averaging roughly $14,570 per person, a notable jump from the 4.6% growth rate seen in 2022. Therefore, the increase in healthcare expenditure is driving the growth of the retinitis pigmentosa industry.

How Will The Drivers Impact Growth In The Global Retinitis Pigmentosa Market?

• Rising Investments In Research And Development (High) – The increasing emphasis on investments in research and development will become a key driver of growth in the retinitis pigmentosa market by 2030. Increased funding from government agencies, pharmaceutical companies, and biotech firms is accelerating the development of innovative therapies, including gene therapy, stem cell treatments, and optogenetics. Advancements in clinical research are expanding the pipeline of potential treatments, improving patient outcomes, and increasing market opportunities. Growing collaborations between research institutions and industry players are also enhancing drug discovery and speeding up regulatory approvals. As a result, the growing deployment of investments in research and development is anticipated to contributing to a 2.0% annual growth in the market. • Rising Strategic Collaborations and Partnerships (Medium) – The growing focus on collaborations and partnerships will emerge as a major factor driving the expansion of the retinitis pigmentosa market by 2030. Pharmaceutical companies, biotech firms, and research institutions are increasingly forming alliances to accelerate the development of gene therapies, stem cell treatments, and innovative drug candidates. These collaborations facilitate knowledge sharing, improve access to advanced technologies, and enhance funding for clinical trials. Consequently, the accelerating adoption of collaborations and partnerships capabilities is projected to contributing to a 1.5% annual growth in the market. • Higher Healthcare Expenditure (Medium) – The expanding integration of healthcare expenditure processes will serve as a key growth catalyst for the retinitis pigmentosa market by 2030. Increased government and private sector spending on healthcare is improving access to advanced diagnostic tools, genetic testing, and innovative treatments such as gene therapy and stem cell-based approaches. Rising investment in ophthalmic research and specialized care facilities is also accelerating drug development and clinical trials. Therefore, this growing integration of healthcare expenditure operations is projected to supporting to a 1.0% annual growth in the market. • Growing Geriatric Population (Low) – The increasing emphasis on geriatric population will become a significant driver contributing to the growth of the retinitis pigmentosa market by 2030. As life expectancy increases, the number of aging individuals at risk of retinal degenerative diseases rises, leading to greater demand for effective treatments. Older adults are more likely to experience vision-related disorders, increasing the need for advanced diagnostic tools, gene therapies, and regenerative medicine. Consequently, the rising adoption of geriatric population strategies is projected to contributing to a 0.5% annual growth in the market.

How Will The Restraints Impact Growth In The Global Retinitis Pigmentosa Market?

• Limited Public And Professional Awareness (High) – Limited Public And Professional Awareness will restrict the growth of the Retinitis Pigmentosa market during the forecast period. Limited awareness of retinitis pigmentosa among healthcare professionals and the general public affects early diagnosis and treatment seeking behavior. Lack of awareness about available treatment options and clinical trials restricts patient access to therapies. Limited professional education about RP management can lead to underdiagnosis and undertreatment, affecting market growth. • Lack of Healthcare Infrastructure (Medium) – Lack of Healthcare Infrastructure will restrict the growth of the Retinitis Pigmentosa market during the forecast period. Retinitis pigmentosa diagnosis and management require specialized ophthalmology equipment and trained specialists. Many regions lack adequate healthcare infrastructure for rare eye disease diagnosis and treatment. Infrastructure gaps limit patient access to RP diagnostic services and therapies, constraining market growth.

Key Players In The Global Retinitis Pigmentosa Market

Major companies operating in the retinitis pigmentosa market are Johnson And Johnson, Novartis AG, AbbVie Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd, Spark Therapeutics, REGENXBIO Inc., Editas Medicine, IVERIC bio, MeiraGTx Holdings, Gensight Biologics, Second Sight Medical Products, Copernicus Therapeutics Inc., Kiora Pharmaceuticals, 4D Molecular Therapeutics, Acucela Inc., AGTC Applied Genetic Technologies Corporation, ProQR Therapeutics NV, Nanoscope Therapeutics Inc, Beacon Therapeutics Ltd, Horama SA, ViGeneron GmbH

Global Retinitis Pigmentosa Market Trends and Insights

Major companies operating in the retinitis pigmentosa market are increasingly focusing on developing innovative treatment options, such as gene therapy, to provide more effective and targeted solutions for managing and potentially curing this debilitating condition. Gene therapy for retinitis pigmentosa (RP) involves the delivery of functional genes to replace or repair the defective ones causing the disease. This innovative treatment aims to restore normal function to the affected photoreceptor cells in the retina, thereby slowing or potentially halting the progression of vision loss. For instance, in April 2024, ViGeneron GmbH, a Germany-based biotechnology company, launched a Phase Ib clinical trial to evaluate the safety, tolerability, and efficacy of VG901, a gene therapy designed to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The trial is an open-label, single-arm, dose-escalation study that will investigate the intravitreal injection of VG901 in patients with autosomal recessive RP due to biallelic CNGA1 mutations.

What Are Latest Mergers And Acquisitions In The Retinitis Pigmentosa Market?

In December 2023, Thea Pharma Inc., a France-based pharmaceutical company, acquired two antisense oligonucleotide (AON) treatments, Sepofarsen (LCA10) and Ultevursen (USH2A), from ProQR Therapeutics NV for an undisclosed amount. This acquisition supports Thea's focus on rare genetic eye diseases and ophthalmology. ProQR Therapeutics NV is a Netherlands-based biotechnology company that focuses on developing treatments for retinitis pigmentosa.

What Defines the Retinitis Pigmentosa Market?

The retinitis pigmentosa market consists of revenues earned by entities by providing services such as genetic counseling, low vision therapy, psychological support, and educational support. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinitis pigmentosa market also includes sales of retinal implants, screen readers, telescopic glasses, and adaptive lighting. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Retinitis Pigmentosa Market Report 2026?

The retinitis pigmentosa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the retinitis pigmentosa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.